Multiply Labs, a robotics company developing industry-leading automated manufacturing systems to produce individualized drugs, and GenScript Biotech Corporation (GenScript), one of the world’s leading providers of life-science research tools and services, today announced a strategic partnership around the automation of the cell isolation phase of cell therapy manufacturing, reducing the complexity of this laborious process.
Cell isolation using immunomagnetic beads is a critical industry-standard process in cell therapy manufacturing. However, the current method of performing this task manually is complex and time-consuming. In addition to the sensitivity of cells, intricate process and precision required, the approach requires manually handling, connecting and double-checking complex closed-system consumable kits.
By utilizing Multiply Labs’ cell therapy robotic cluster and GenScript’s GMP-grade CytoSinct 1000 cell isolation solution, capable of isolating up to 120X10^9 total cells within a single hour, this collaboration will introduce the first fully automated solution for bead-based cell isolation. Importantly, this automation technology will not require cell therapy manufacturers to make substantial modifications to their original manufacturing processes.
This advancement promises to mitigate the risk of human error while simultaneously boosting cell therapy output. Once this part of the process can be run without human intervention, manufacturing operators and process scientists will be free to oversee the production of more therapies at once, without being tied down in the delicate, tedious, and mission-critical manual tasks involved in the traditional manufacturing process. Automation in this deeply time-consuming area of the process will therefore drive significant benefits around efficiency, and ultimately support the scalability of cell therapies.
“Our collaboration with Multiply Labs marks a significant advancement in personalized medicine and the potential impact of cell therapies,” said Ray Chen, PhD, President of Life Science Group at GenScript. “By automating our industry-leading solution, we can dramatically increase productivity and scale operations to unprecedented levels.”
“We’re thrilled to partner with GenScript to enhance a critical aspect of the cell therapy process through automation,” said Fred Parietti, PhD, Co-Founder and CEO of Multiply Labs. “This collaboration advances our goal of a fully automated, end-to-end cell therapy manufacturing process, reducing costs and expanding patient access to life-changing treatments.”
About Multiply Labs
Multiply Labs is a robotics company that provides autonomous manufacturing technology to the pharmaceutical industry. The company develops advanced, cloud-controlled robotic systems that enable the production of individualized drugs at scale. Its customers include some of the largest global organizations in the advanced pharmaceutical manufacturing space. Multiply Labs’ expertise is at the intersection of robotics and biopharma – its team includes mechanical engineers, electrical engineers, computer scientists, software engineers and pharmaceutical scientists. The founding team got in touch because of their shared love of robots at MIT. The company is based in San Francisco, California. For more information, please visit www.multiplylabs.com.
About GenScript Biotech Corporation
GenScript Biotech Corporation (HK:1548) is the world’s leading technology and service provider of life-science R&D and manufacturing. Built upon its solid gene synthesis technology, GenScript Biotech is divided into four major platforms: the life-science service and product platform, the biologics contract development and manufacturing organization (CDMO) platform, the industrial synthetic products platform, and the integrated global cell therapy platform.
GenScript Biotech was founded in New Jersey, USA in 2002 and listed on the Hong Kong Stock Exchange in 2015. GenScript Biotech’s business operations span over 100 countries and regions worldwide, with legal entities of its affiliated companies located in the US, Mainland & Hong Kong China, Japan, Singapore, Netherlands, Ireland, the United Kingdom, Korea, and Belgium. GenScript Biotech provides premium, convenient, and reliable services and products for more than 200,000 global customers.
As of June 30, 2023, GenScript Biotech had more than 6,400 employees globally. The company owns numerous intellectual property rights, including over 240 patents, over 900 pending- patent applications, and a significant number of trade secrets.
Driven by the corporate mission of “make people and nature healthier through biotechnology”, GenScript Biotech strives to become the most trustworthy biotech company in the world. As of December 31, 2023, 87,745 peer-reviewed journal articles worldwide have cited GenScript Biotech’s services and products. For more information, please visit GenScript Biotech’s official website genscript.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240425915801/en/